Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
Status:
Recruiting
Trial end date:
2026-06-24
Target enrollment:
Participant gender:
Summary
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of
SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild
Alzheimer's Disease.